JP2002338473A - Anti-fatigue composition - Google Patents

Anti-fatigue composition

Info

Publication number
JP2002338473A
JP2002338473A JP2001144240A JP2001144240A JP2002338473A JP 2002338473 A JP2002338473 A JP 2002338473A JP 2001144240 A JP2001144240 A JP 2001144240A JP 2001144240 A JP2001144240 A JP 2001144240A JP 2002338473 A JP2002338473 A JP 2002338473A
Authority
JP
Japan
Prior art keywords
ribose
fatigue
imidazole compound
anserine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001144240A
Other languages
Japanese (ja)
Inventor
Yoshiharu Matahira
芳春 又平
Kazuaki Kikuchi
数晃 菊地
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yaizu Suisan Kagaku Kogyo Co Ltd
Original Assignee
Yaizu Suisan Kagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yaizu Suisan Kagaku Kogyo Co Ltd filed Critical Yaizu Suisan Kagaku Kogyo Co Ltd
Priority to JP2001144240A priority Critical patent/JP2002338473A/en
Priority to US09/933,438 priority patent/US6855727B2/en
Priority to TW090120843A priority patent/TWI221413B/en
Priority to AT01307418T priority patent/ATE345798T1/en
Priority to KR1020010053099A priority patent/KR100805163B1/en
Priority to DE60124658T priority patent/DE60124658T2/en
Priority to EP01307418A priority patent/EP1210940B1/en
Priority to CN01141170A priority patent/CN1356103A/en
Publication of JP2002338473A publication Critical patent/JP2002338473A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To provide a functional food material utilizing extracts obtained from fishes and shellfishes, chicken, meat, etc. SOLUTION: This anti-fatigue composition having antifatigue effect is obtained by including an imidazole compound and D-ribose as active ingredients. In the antifatigue composition, the imidazole compound includes, preferably, at least one or more kinds of histidine, anserine, carnosine, balenine and salts thereof. The composition comprises, preferably, 5-50 wt.% of the imidazole compound and 5-50 wt.% of the D-ribose.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、特に魚介類、鳥
肉、畜肉等から得られるイミダゾール化合物及びD−リ
ボースを利用した抗疲労組成物に関する。
The present invention relates to an anti-fatigue composition using an imidazole compound and D-ribose obtained from fish, shellfish, poultry, livestock meat and the like.

【0002】[0002]

【従来の技術】激しい運動を行なうと、筋肉にあるグリ
コーゲン由来のグルコースが利用され、無酸素的な解糖
反応が進行して筋肉の収縮に必要なATPが合成され
る。そして、その代謝産物である乳酸が蓄積して筋肉内
pHの低下が起こり、筋収縮の効率が落ちてくる。この
状態は代謝性アシドーシスと言われており、その結果、
筋肉疲労に至ると考えられている。そのため、持続的な
運動による筋肉疲労を抑制するためには、代謝性アシド
ーシスを引き起こさないことが重要である。
2. Description of the Related Art When intense exercise is performed, glucose derived from glycogen in muscle is used, and an anaerobic glycolysis reaction proceeds to synthesize ATP necessary for muscle contraction. Then, lactic acid, which is a metabolite thereof, accumulates to cause a decrease in intramuscular pH, and the efficiency of muscle contraction decreases. This condition is called metabolic acidosis, and as a result,
It is thought to lead to muscle fatigue. Therefore, in order to suppress muscle fatigue due to continuous exercise, it is important not to cause metabolic acidosis.

【0003】近年、スポーツ選手の間でサプリメントと
してクレアチンの摂取が盛んに行われている。クレアチ
ンは体内でクレアチンリン酸に変換され、高エネルギー
リン酸化合物としてエネルギーを運搬する働きを有し、
またATPの合成に不可欠な成分であり、クレアチンの
摂取により筋肉のクレアチン含量が増加し、高強度の運
動のパフォーマンスが向上することが知られている(Ha
rris, R. C. et al:Clin. Sci., 83, 367-374, 199
2)。
[0003] In recent years, creatine has been actively taken as a supplement among athletes. Creatine is converted to creatine phosphate in the body and has the function of transferring energy as a high-energy phosphate compound,
It is also an essential component of ATP synthesis, and it is known that ingestion of creatine increases the creatine content of muscle and improves the performance of high-intensity exercise (Ha
rris, RC et al: Clin. Sci., 83, 367-374, 199
2).

【0004】また、エネルギー源としてのグリコーゲン
が不足すると、体脂肪がより利用されやすくなると共に
血中アミノ酸がエネルギーに変換されることから、血中
アミノ酸の濃度をできるだけ高め、エネルギー源として
利用して筋肉疲労や筋力低下を改善する試みもなされて
いる。特にエネルギー源として利用されやすいアミノ酸
は、分岐鎖アミノ酸(ロイシン、イソロイシン、バリ
ン)であり、例えば特開昭58−16577号、特開平
7−25838号及び特開2000−26290号に
は、上記分岐鎖アミノ酸を食品として利用することが提
案されている。
[0004] In addition, when glycogen as an energy source is insufficient, body fat is more easily used and blood amino acids are converted into energy. Therefore, the concentration of blood amino acids is increased as much as possible and used as an energy source. Attempts have been made to improve muscle fatigue and muscle weakness. Amino acids particularly easily used as an energy source are branched-chain amino acids (leucine, isoleucine, and valine). For example, Japanese Patent Application Laid-Open Nos. It has been proposed to utilize chain amino acids as foods.

【0005】さらに、特開平8−198748号及び特
開平9−249556号には、運動機能の向上と疲労回
復効果を目的として、スズメバチ(Vespar属)の幼虫が
分泌する唾液に含まれるアミノ酸類に準じて構成された
アミノ酸組成物を投与することにより、血中アミノ酸の
変動を抑制することが提案されている。
Further, Japanese Patent Application Laid-Open Nos. Hei 8-198748 and Hei 9-249556 disclose amino acids contained in saliva secreted by larvae of hornets (Vespar) for the purpose of improving motor function and recovering from fatigue. It has been proposed to suppress fluctuations in blood amino acids by administering an amino acid composition configured in accordance with the composition.

【0006】[0006]

【発明が解決しようとする課題】ところで、魚介類、鳥
肉、畜肉等から得られるエキス類は様々なアミノ酸類を
含んでおり、一般には調味料として広く利用されている
が、その生理活性機能についてはほとんど研究されてい
ない。
By the way, extracts obtained from fish, shellfish, poultry meat, animal meat and the like contain various amino acids and are generally widely used as seasonings. Has been little studied.

【0007】従って、本発明の目的は、魚介類、鳥肉、
畜肉等から得られるエキス類を利用した機能性食品素材
を提供することにある。
Accordingly, an object of the present invention is to provide fish, seafood, poultry,
It is to provide a functional food material using extracts obtained from livestock meat and the like.

【0008】[0008]

【課題を解決するための手段】本発明者らは、カツオや
マグロの肉から調製された調味料エキスの生理活性機能
を研究する過程で該エキス中に多量に含まれるイミダゾ
ール化合物に着目し、鋭意研究した結果、該イミダゾー
ル化合物が抗疲労効果を有することを発見した。さら
に、該イミダゾール化合物とD−リボースとを併用する
ことにより、より優れた抗疲労効果が得られることを見
出し、これらの事実に基づいて本発明を完成するに至っ
た。
Means for Solving the Problems The present inventors have focused on imidazole compounds contained in a large amount in a seasoning extract prepared from skipjack or tuna meat in the course of studying the physiologically active function of the extract. As a result of intensive studies, they have found that the imidazole compound has an anti-fatigue effect. Furthermore, they have found that a better anti-fatigue effect can be obtained by using the imidazole compound and D-ribose in combination, and based on these facts, have completed the present invention.

【0009】本発明の抗疲労組成物は、イミダゾール化
合物及びD−リボースを有効成分として含有することを
特徴とする。
The anti-fatigue composition of the present invention is characterized by containing an imidazole compound and D-ribose as active ingredients.

【0010】本発明においては、前記イミダゾール化合
物が、ヒスチジン、アンセリン、カルノシン、バレニン
及びそれらの塩から選ばれた少なくとも1種以上である
ことが好ましい。
In the present invention, the imidazole compound is preferably at least one selected from histidine, anserine, carnosine, varenin and salts thereof.

【0011】また、前記イミダゾール化合物を5〜50
質量%、前記D−リボースを5〜50質量%含有するこ
とが好ましい。
The imidazole compound may be used in an amount of 5 to 50.
It is preferable to contain 5 to 50% by mass of the D-ribose.

【0012】本発明によれば、従来、調味料として利用
されてきた魚介類、鳥肉、畜肉等から得られるエキス類
を利用して、経口摂取することにより、運動時若しくは
運動後の筋肉疲労等を低減できる抗疲労組成物を提供で
きる。
According to the present invention, muscle fatigue during or after exercise is obtained by ingesting orally using extracts obtained from fish, shellfish, poultry, animal meat, etc. which have been conventionally used as seasonings. It is possible to provide an anti-fatigue composition capable of reducing the like.

【0013】また、本発明においては、さらにタウリ
ン、クレアチン、ビタミンE、ビタミンC、カロテノイ
ド、還元型グルタチオン、ミネラル類から選ばれた1種
以上を含有することが好ましい。この態様によれば、上
記各成分の有する生理活性効果を付与した抗疲労組成物
を提供できる。
Further, in the present invention, it is preferable to further contain at least one selected from taurine, creatine, vitamin E, vitamin C, carotenoid, reduced glutathione, and minerals. According to this aspect, it is possible to provide an anti-fatigue composition provided with the physiologically active effect of each of the above components.

【0014】[0014]

【本発明の実施形態】本発明の抗疲労組成物の有効成分
の一つであるイミダゾール化合物としては、具体的には
ヒスチジン、アンセリン(β−アラニル−1−メチルヒ
スチジン)、カルノシン(β−アラニルヒスチジン)、
バレニン(β−アラニル−3−メチルヒスチジン)等が
挙げられる。本発明においては、ヒスチジン、アンセリ
ン、カルノシン、バレニン及びそれらの塩から選ばれた
少なくとも1種以上を有効成分として含有することが好
ましい。また、上記の塩としては、塩酸、乳酸、酢酸、
硫酸、クエン酸、アスコルビン酸、リンゴ酸、コハク
酸、アジピン酸、グルコン酸、酒石酸等の塩が挙げられ
る。
BEST MODE FOR CARRYING OUT THE INVENTION As the imidazole compound which is one of the active ingredients of the anti-fatigue composition of the present invention, specifically, histidine, anserine (β-alanyl-1-methylhistidine), carnosine (β-ara Nylhistidine),
Valenin (β-alanyl-3-methylhistidine) and the like. In the present invention, it is preferable that at least one selected from histidine, anserine, carnosine, varenin and salts thereof is contained as an active ingredient. Further, as the above salts, hydrochloric acid, lactic acid, acetic acid,
Salts such as sulfuric acid, citric acid, ascorbic acid, malic acid, succinic acid, adipic acid, gluconic acid, tartaric acid and the like can be mentioned.

【0015】上記イミダゾール化合物は、魚肉、鶏肉、
畜肉等に含まれており、それらから水抽出、熱水抽出、
アルコール抽出、超臨界抽出等の方法により抽出したエ
キスを精製することにより得ることができる。
The above imidazole compound is used for fish meat, chicken meat,
It is contained in meat, etc., from which water extraction, hot water extraction,
It can be obtained by purifying an extract extracted by a method such as alcohol extraction or supercritical extraction.

【0016】例えば、アンセリンは以下のようにして得
ることができる。まず、常法に従ってカツオ、マグロ、
ウシ、ニワトリ等の肉からエキスを調製し、適宜水を加
えて該エキスのブリックス(Bx.)を1〜10%に調
整した後、限外濾過膜(分画分子量5,000〜50,
000)を用いて高分子タンパク質を除去し、低分子ペ
プチド画分を回収する。次いで、文献(Suyama et al:
Bull. Japan. Soc. Scient. Fish., 33, 141-146, 196
7)の方法に従って、適宜濃縮した低分子ペプチド画分
を、強酸性樹脂を用いたイオン交換クロマトグラフィー
に供し、溶出液を回収する。そして、この溶出液を脱塩
した後pH調整し、凍結乾燥等により乾燥して得ること
ができる。
For example, anserine can be obtained as follows. First, skipjack, tuna,
An extract is prepared from meat such as cows and chickens, and water is appropriately added to adjust the Brix (Bx.) Of the extract to 1 to 10%.
000) to remove the high molecular weight protein and collect the low molecular weight peptide fraction. Then, the literature (Suyama et al:
Bull. Japan. Soc. Scient. Fish., 33, 141-146, 196
According to the method of 7), the appropriately concentrated low molecular peptide fraction is subjected to ion exchange chromatography using a strongly acidic resin, and an eluate is collected. Then, the eluate can be obtained by desalting, adjusting the pH, and drying by freeze-drying or the like.

【0017】また、カルノシンはブタ肉を原料として、
バレニンは鯨肉(例えばヒゲクジラ類)を原料として、
上記と同様の方法により得ることができる。
Carnosine is made from pork as a raw material.
Valenin is made from whale meat (eg baleen whales)
It can be obtained by a method similar to the above.

【0018】本発明の抗疲労組成物は、上記イミダゾー
ル化合物を5〜50質量%含むことが好ましく、10〜
50質量%含むことがより好ましい。上記イミダゾール
化合物の含有量が5質量%未満であると充分な抗疲労効
果が期待できず、50質量%超であると飲食品の味に影
響を与えるため好ましくない。
The anti-fatigue composition of the present invention preferably contains 5 to 50% by mass of the above imidazole compound.
More preferably, it contains 50% by mass. When the content of the imidazole compound is less than 5% by mass, a sufficient anti-fatigue effect cannot be expected.

【0019】また、本発明の抗疲労組成物のもう一つの
有効成分であるD−リボースは、アルドペントースに属
する単糖であり、天然にはリン酸と結合してヌクレオシ
ド、ヌクレオチドとして存在する。本発明においては、
市販のものを用いることができ、例えば和光純薬株式会
社等から購入することができる。
D-ribose, another active ingredient of the anti-fatigue composition of the present invention, is a monosaccharide belonging to aldopentoose and naturally exists as a nucleoside or nucleotide by binding to phosphate. In the present invention,
A commercially available product can be used, and can be purchased, for example, from Wako Pure Chemical Industries, Ltd.

【0020】本発明の抗疲労組成物は、D−リボースを
5〜50質量%含むことが好ましく、10〜50質量%
含むことがより好ましい。D−リボースの含有量が5質
量%未満であると充分な抗疲労効果が期待できず、50
質量%超であると吸湿や着色の問題が生じるため好まし
くない。
The anti-fatigue composition of the present invention preferably contains D-ribose in an amount of 5 to 50% by mass, more preferably 10 to 50% by mass.
More preferably, it is included. If the D-ribose content is less than 5% by mass, a sufficient anti-fatigue effect cannot be expected, and
If it is more than mass%, problems such as moisture absorption and coloring occur, which is not preferable.

【0021】なお、上記イミダゾール化合物とD−リボ
ースの配合割合は、質量比(イミダゾール化合物:D−
リボース)で1:10〜10:1が好ましい。イミダゾ
ール化合物とD−リボースの配合割合が上記範囲外であ
ると相乗的な抗疲労効果が期待できない。
The mixing ratio of the above-mentioned imidazole compound and D-ribose is based on the mass ratio (imidazole compound: D-ribose).
Ribose) is preferably 1:10 to 10: 1. If the mixing ratio of the imidazole compound and D-ribose is outside the above range, a synergistic anti-fatigue effect cannot be expected.

【0022】また、本発明の抗疲労組成物は、さらにタ
ウリン、クレアチン、ビタミンE、ビタミンC、カロテ
ノイド、還元型グルタチオン、ミネラル類から選ばれた
1種以上を含有することが好ましい。上記成分を配合す
ることにより、各成分の有する生理活性効果、例えばタ
ウリンやクレアチン等の抗疲労効果、ビタミンE、ビタ
ミンC、カロテノイド、還元型グルタチオン等の抗酸化
効果等が期待できる。なお、上記ミネラル類としては、
飲食品に使用可能な微量金属元素、例えばカルシウム、
ナトリウム、マグネシウム、セレン、鉄、亜鉛等が挙げ
られる。
The anti-fatigue composition of the present invention preferably further contains at least one selected from taurine, creatine, vitamin E, vitamin C, carotenoid, reduced glutathione, and minerals. By blending the above components, the physiologically active effects of each component, for example, anti-fatigue effects such as taurine and creatine, and antioxidant effects such as vitamin E, vitamin C, carotenoid, reduced glutathione, etc. can be expected. In addition, as said minerals,
Trace metal elements that can be used in food and drink, such as calcium,
Examples include sodium, magnesium, selenium, iron, zinc and the like.

【0023】本発明の抗疲労組成物は、上記基本的成分
の他に、賦形剤、糖類、香料、色素、油脂類、タンパク
質等を適宜含むことができる。
The anti-fatigue composition of the present invention can appropriately contain excipients, sugars, fragrances, pigments, oils and fats, proteins and the like in addition to the above basic components.

【0024】本発明の抗疲労組成物の製品形態は特に制
限されず、使用形態に合わせて適宜選択でき、例えば錠
剤、粉末、顆粒、カプセル剤、ペースト、溶液等が挙げ
られる。
The product form of the anti-fatigue composition of the present invention is not particularly limited and can be appropriately selected according to the use form, and examples thereof include tablets, powders, granules, capsules, pastes, and solutions.

【0025】本発明の抗疲労組成物の1日当りの有効摂
取量は、イミダゾール化合物及びD−リボースの合計量
換算で1〜200mg/体重kg、より好ましくは5〜
30mg/体重kgである。
The effective daily intake of the anti-fatigue composition of the present invention is 1 to 200 mg / kg of body weight, more preferably 5 to 5 in terms of the total amount of the imidazole compound and D-ribose.
30 mg / kg of body weight.

【0026】また、本発明の抗疲労組成物を、清涼飲
料、錠菓、スナック、粉末スープ、ソーセージ等の飲食
品に添加してもよい。その場合、一食当りの添加量はイ
ミダゾール化合物及びD−リボースの合計量換算で10
0〜2000mgが好ましく、400〜2000mgが
より好ましい。イミダゾール化合物及びD−リボースの
合計添加量が100mg未満であると抗疲労効果があま
り期待できず、2000mg超であると飲食品の味に影
響がでるため好ましくない。
The anti-fatigue composition of the present invention may be added to foods and drinks such as soft drinks, tablets, snacks, powdered soups and sausages. In that case, the amount added per serving is 10 in terms of the total amount of the imidazole compound and D-ribose.
The amount is preferably from 0 to 2000 mg, more preferably from 400 to 2000 mg. If the total amount of the imidazole compound and D-ribose is less than 100 mg, the anti-fatigue effect cannot be expected so much, and if it exceeds 2000 mg, the taste of food and drink is adversely affected, which is not preferable.

【0027】[0027]

【実施例】以下、実施例を挙げて本発明を具体的に説明
する。 実施例1 常法に従って調製したカツオエキス(Bx.=55%)
10kgに、4倍量の水を加えて希釈した後、限外濾過
(UF)膜(分画分子量10,000)を用いて高分子
タンパク質を除去し、低分子ペプチド画分を回収した。
この画分を濃縮して、0.38Nクエン酸ナトリウム水
溶液(pH4.0)で平衡化した強酸性樹脂(商品名
「Amberlite IR-120」、ロームアンドハース社製)を充
填したカラムクロマトグラフィーに供し、樹脂容量の
4.5〜6.0倍の0.38Nクエン酸ナトリウム水溶
液(pH4.0)で溶出して溶出画分を回収した(Suya
ma etal:Bull. Japan. Soc. Scient. Fish., 33, 141-
146, 1967参照)。そして、この溶液を脱塩し、pH調
整した後、凍結乾燥して、粉末45gを得た。この粉末
について日立製アミノ酸分析計により分析したところ、
アンセリン塩酸塩として98%の純度であった。
The present invention will be specifically described below with reference to examples. Example 1 Skipjack extract (Bx. = 55%) prepared according to a conventional method
After diluting 10 kg with 4 times the volume of water, the high molecular weight protein was removed using an ultrafiltration (UF) membrane (molecular weight cut off 10,000), and a low molecular weight peptide fraction was collected.
This fraction was concentrated and subjected to column chromatography packed with a strongly acidic resin (trade name “Amberlite IR-120”, manufactured by Rohm and Haas) equilibrated with a 0.38N aqueous sodium citrate solution (pH 4.0). The solution was eluted with a 0.38N aqueous sodium citrate solution (pH 4.0) 4.5 to 6.0 times the resin volume to collect an eluted fraction (Suya
ma etal: Bull. Japan. Soc. Scient. Fish., 33, 141-
146, 1967). Then, the solution was desalted, adjusted for pH, and freeze-dried to obtain 45 g of powder. When this powder was analyzed with a Hitachi amino acid analyzer,
The purity was 98% as anserine hydrochloride.

【0028】実施例2 実施例1で調製したアンセリン塩酸塩及びD−リボース
(和光純薬工業製)を用いて以下の動物実験を行った。
Example 2 The following animal experiments were performed using anserine hydrochloride prepared in Example 1 and D-ribose (manufactured by Wako Pure Chemical Industries, Ltd.).

【0029】6週齢の雄SPFマウス40匹を4群(各
群10匹)に分け、4時間絶食させた後、対照群には注
射用水を、アンセリン投与群にはアンセリン塩酸塩の水
溶液(40mg/ml)をアンセリン塩酸塩換算で20
0mg/kg体重となるように、リボース投与群にはD
−リボースの水溶液(40mg/ml)をD−リボース
換算で200mg/kg体重となるように、アンセリン
−リボース混合物投与群にはアンセリン塩酸塩とD−リ
ボースを1:1の質量比で配合した混合物の水溶液(4
0mg/ml)をアンセリン塩酸塩及びD−リボースの
合計量換算で200mg/kg体重となるように、それ
ぞれ強制的に経口投与した。
Forty male SPF mice, 6 weeks old, were divided into 4 groups (10 mice in each group) and fasted for 4 hours. After that, water for injection was used for the control group, and an aqueous solution of anserine hydrochloride (for the anserine administration group). 40 mg / ml) by 20 as anserine hydrochloride.
0 mg / kg body weight, D
-Anserine-ribose mixture administration group is a mixture of anserine hydrochloride and D-ribose in a mass ratio of 1: 1 so that an aqueous solution of ribose (40 mg / ml) becomes 200 mg / kg body weight in terms of D-ribose. Aqueous solution (4
(0 mg / ml) was forcibly administered orally so that the total amount of anserine hydrochloride and D-ribose was 200 mg / kg body weight.

【0030】経口投与してから正確に1時間後に以下の
強制運動をマウスに負荷した。水温20℃の水を満たし
て空気を送り込み水面を波立たせた水槽(ポリサルフォ
ン製ケージ、外径265W×427D×204Hmm)
に、マウスを入れて遊泳時間の測定を行なった。なお、
マウスには、マウスの平均体重の10%に相当する重り
を負荷し、遊泳開始からマウスが頭部を水面下に7秒以
上沈めるまでの時間を遊泳時間として測定した。
Mice were subjected to the following forced exercise exactly one hour after oral administration. A water tank (polysulfone cage, outer diameter 265W × 427D × 204Hmm) filled with water at a water temperature of 20 ° C and fed with air to make the water surface ruffled.
Then, the mouse was put into the tank and the swimming time was measured. In addition,
The mouse was loaded with a weight equivalent to 10% of the average weight of the mouse, and the time from the start of swimming until the mouse sank its head under the water surface for at least 7 seconds was measured as the swimming time.

【0031】そして、上記の運動負荷後、採血して血漿
を分離し、血漿中の乳酸量を、市販の「F−キット L
−乳酸」(商品名、ベーリンガーマンハイム株式会社
製)を用いて測定した。なお、上記の各測定結果は平均
値±標準誤差で表し、有意差の検定は、Student's t-te
stにより行なった。
After the above exercise load, blood is collected to separate plasma, and the amount of lactic acid in the plasma is measured using a commercially available “F-kit L”.
-Lactic acid "(trade name, manufactured by Boehringer Mannheim Co., Ltd.). Each of the above measurement results is represented by an average value ± standard error, and a test for a significant difference was performed using Student's t-te
Performed by st.

【0032】図1には、各群の遊泳時間の結果が示され
ている。図1から、対照群に比べてアンセリン投与群、
リボース投与群及びアンセリン−リボース混合物投与群
は遊泳時間が長くなる傾向が認められた。特にアンセリ
ン−リボース混合物投与群は、他の群に比べて有意に遊
泳時間が長いことが分かる。
FIG. 1 shows the results of the swimming time of each group. From FIG. 1, the anserine administration group,
In the ribose-administered group and the anserine-ribose mixture-administered group, the swimming time tended to be longer. In particular, it can be seen that the anserine-ribose mixture administration group has a significantly longer swimming time than the other groups.

【0033】図2には、運動負荷後の血漿乳酸量が示さ
れている。図2から、対照群に比べてアンセリン投与群
(23.9%減少)、リボース投与群(29.4%減
少)及びアンセリン−リボース混合物投与群(42.0
%減少)の血漿乳酸量は、有意に低く抑えられているこ
とが分かる。
FIG. 2 shows the plasma lactate level after exercise. 2, the anserine administration group (23.9% decrease), the ribose administration group (29.4% decrease), and the anserine-ribose mixture administration group (42.0%) as compared to the control group.
% Decrease) is found to be significantly lower.

【0034】以上の結果から、各群の投与量(200m
g/kg体重)が一定であることを考慮すれば、アンセ
リン又はD−リボースを単独で用いた場合に比べて、ア
ンセリンとD−リボースを併用することにより、相乗的
に疲労を低減できることが示唆された。
From the above results, the dose of each group (200 m
g / kg body weight), it is suggested that fatigue can be reduced synergistically by using anserine and D-ribose together, compared to the case of using anserine or D-ribose alone. Was done.

【0035】実施例3 本発明の抗疲労組成物を配合した飲食品の配合例を示
す。表1はスポーツ栄養飲料、表2は錠剤の配合例であ
る。
Example 3 An example of the formulation of a food or drink containing the anti-fatigue composition of the present invention is shown. Table 1 shows a sports nutritional drink, and Table 2 shows a formulation example of a tablet.

【0036】[0036]

【表1】 [Table 1]

【0037】[0037]

【表2】 [Table 2]

【0038】[0038]

【発明の効果】以上説明したように本発明によれば、イ
ミダゾール化合物及びD−リボースを有効成分として含
有させることにより、優れた抗疲労効果を有する抗疲労
組成物を提供できる。
As described above, according to the present invention, an anti-fatigue composition having an excellent anti-fatigue effect can be provided by containing an imidazole compound and D-ribose as active ingredients.

【図面の簡単な説明】[Brief description of the drawings]

【図1】 マウスの遊泳時間測定の結果を示す図であ
る。
FIG. 1 is a diagram showing the results of measuring the swimming time of mice.

【図2】 運動負荷後におけるマウスの血漿中の乳酸量
を示す図である。
FIG. 2 is a graph showing the amount of lactic acid in the plasma of mice after exercise.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A23L 2/52 A61K 31/198 A61K 31/198 31/202 31/202 31/203 31/203 31/255 31/255 31/375 31/375 31/4172 31/4172 33/00 33/00 A61P 3/02 38/00 A23L 2/00 F A61P 3/02 A61K 37/02 Fターム(参考) 4B017 LC03 LE01 LE10 LK01 LK11 LK14 LK15 LK16 LK17 LP01 LP08 4B018 LB08 LE01 LE05 MD01 MD05 MD19 MD20 MD23 MD25 MD26 MD27 MD70 MD74 ME14 MF01 MF02 4C084 AA01 AA02 AA03 BA01 BA08 BA14 BA24 CA20 CA21 CA41 CA45 DC31 MA02 MA16 MA35 MA52 NA14 ZB21 ZC21 4C086 AA01 AA02 BC38 EA01 MA02 MA03 MA04 MA16 MA35 MA52 NA14 ZB21 ZC21 4C206 AA01 AA02 DA12 FA51 JA08 KA01 MA02 MA03 MA04 MA36 MA55 MA72 NA14 ZB21 ZC21 ZC28 ZC29 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A23L 2/52 A61K 31/198 A61K 31/198 31/202 31/202 31/203 31/203 31/255 31/255 31/375 31/375 31/4172 31/4172 33/00 33/00 A61P 3/02 38/00 A23L 2/00 F A61P 3/02 A61K 37/02 F term (reference) 4B017 LC03 LE01 LE10 LK01 LK11 LK14 LK15 LK16 LK17 LP01 LP08 4B018 LB08 LE01 LE05 MD01 MD05 MD19 MD20 MD23 MD25 MD26 MD27 MD70 MD74 ME14 MF01 MF02 4C084 AA01 AA02 AA03 BA01 BA08 BA14 BA24 CA20 CA21 CA41 CA45 DC31 MA02 A01 A35 MA02 A35 MA01 MA02 MA01 MA01 MA02 MA03 MA04 MA16 MA35 MA52 NA14 ZB21 ZC21 4C206 AA01 AA02 DA12 FA51 JA08 KA01 MA02 MA03 MA04 MA36 MA55 MA72 NA14 ZB21 ZC21 ZC28 ZC29

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 イミダゾール化合物及びD−リボースを
有効成分として含有することを特徴とする抗疲労組成
物。
1. An anti-fatigue composition comprising an imidazole compound and D-ribose as active ingredients.
【請求項2】 前記イミダゾール化合物が、ヒスチジ
ン、アンセリン、カルノシン、バレニン及びそれらの塩
から選ばれた少なくとも1種以上である、請求項1に記
載の抗疲労組成物。
2. The anti-fatigue composition according to claim 1, wherein the imidazole compound is at least one selected from histidine, anserine, carnosine, varenin and salts thereof.
【請求項3】 前記イミダゾール化合物を5〜50質量
%、前記D−リボースを5〜50質量%含有する、請求
項1又は2に記載の抗疲労組成物。
3. The anti-fatigue composition according to claim 1, comprising 5 to 50% by mass of the imidazole compound and 5 to 50% by mass of the D-ribose.
【請求項4】 さらにタウリン、クレアチン、ビタミン
E、ビタミンC、カロテノイド、還元型グルタチオン、
ミネラル類から選ばれた1種以上を含有する、請求項1
〜3のいずれか一つに記載の抗疲労組成物。
4. Taurine, creatine, vitamin E, vitamin C, carotenoid, reduced glutathione,
2. The composition according to claim 1, which comprises at least one selected from minerals.
4. The anti-fatigue composition according to any one of items 1 to 3.
JP2001144240A 2000-12-04 2001-05-15 Anti-fatigue composition Pending JP2002338473A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2001144240A JP2002338473A (en) 2001-05-15 2001-05-15 Anti-fatigue composition
US09/933,438 US6855727B2 (en) 2000-12-04 2001-08-20 Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
TW090120843A TWI221413B (en) 2000-12-04 2001-08-24 Antifatigue composition
AT01307418T ATE345798T1 (en) 2000-12-04 2001-08-31 ANTI-FATIGUE COMPOSITIONS CONTAINING ANSERINE AND D-RIBOSE
KR1020010053099A KR100805163B1 (en) 2000-12-04 2001-08-31 Antifatigue composition
DE60124658T DE60124658T2 (en) 2000-12-04 2001-08-31 Fatigue compositions containing anserine and D-ribose
EP01307418A EP1210940B1 (en) 2000-12-04 2001-08-31 Antifatigue composition comprising anserine and D-ribose
CN01141170A CN1356103A (en) 2000-12-04 2001-10-08 Anti-Fatigue Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001144240A JP2002338473A (en) 2001-05-15 2001-05-15 Anti-fatigue composition

Publications (1)

Publication Number Publication Date
JP2002338473A true JP2002338473A (en) 2002-11-27

Family

ID=18990221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001144240A Pending JP2002338473A (en) 2000-12-04 2001-05-15 Anti-fatigue composition

Country Status (1)

Country Link
JP (1) JP2002338473A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087022A1 (en) * 2004-03-12 2005-09-22 Ajinomoto Co., Inc. Food composition having antistress effect
JP2005278569A (en) * 2004-03-30 2005-10-13 Yaizu Suisankagaku Industry Co Ltd High octopine-containing fish and shellfish extract, method for producing the same, and food and drink containing the high octopine-containing fish and shellfish extract
JP2005336176A (en) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd Body fatigue restorer
WO2006123436A1 (en) * 2005-05-19 2006-11-23 Nippon Meat Packers, Inc. Food for improving motor function
WO2007029834A1 (en) * 2005-09-09 2007-03-15 Ajinomoto Co., Inc. Food composition
WO2007142286A1 (en) * 2006-06-07 2007-12-13 Kyowa Hakko Bio Co., Ltd. Fatigue-reducing agent
JP2008035714A (en) * 2006-08-01 2008-02-21 Wakasa Seikatsu:Kk Health food
US7498301B2 (en) 2003-05-30 2009-03-03 Lytone Enterprise, Inc. Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide
JP2009120564A (en) * 2007-11-16 2009-06-04 Maruha Nichiro Foods Inc Hyaluronic acid production-promoting substance
JP2015097507A (en) * 2013-11-19 2015-05-28 国立大学法人九州大学 Mitochondria activator

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01175939A (en) * 1987-12-29 1989-07-12 Roncari Raymond A Composition for increasing intracellular atp concentration, living body activity level and wound restoration ratio
JPH01246218A (en) * 1988-03-28 1989-10-02 Nippon Univ Immunoregulator

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01175939A (en) * 1987-12-29 1989-07-12 Roncari Raymond A Composition for increasing intracellular atp concentration, living body activity level and wound restoration ratio
JPH01246218A (en) * 1988-03-28 1989-10-02 Nippon Univ Immunoregulator

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498301B2 (en) 2003-05-30 2009-03-03 Lytone Enterprise, Inc. Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide
JPWO2005087022A1 (en) * 2004-03-12 2008-01-24 味の素株式会社 Food composition having anti-stress effect
WO2005087022A1 (en) * 2004-03-12 2005-09-22 Ajinomoto Co., Inc. Food composition having antistress effect
JP2005278569A (en) * 2004-03-30 2005-10-13 Yaizu Suisankagaku Industry Co Ltd High octopine-containing fish and shellfish extract, method for producing the same, and food and drink containing the high octopine-containing fish and shellfish extract
JP2005336176A (en) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd Body fatigue restorer
WO2006123436A1 (en) * 2005-05-19 2006-11-23 Nippon Meat Packers, Inc. Food for improving motor function
JPWO2006123436A1 (en) * 2005-05-19 2008-12-25 日本ハム株式会社 Motor function improving food
WO2007029834A1 (en) * 2005-09-09 2007-03-15 Ajinomoto Co., Inc. Food composition
WO2007142286A1 (en) * 2006-06-07 2007-12-13 Kyowa Hakko Bio Co., Ltd. Fatigue-reducing agent
JP5085541B2 (en) * 2006-06-07 2012-11-28 協和発酵バイオ株式会社 Fatigue reducing agent
JP2008035714A (en) * 2006-08-01 2008-02-21 Wakasa Seikatsu:Kk Health food
JP2009120564A (en) * 2007-11-16 2009-06-04 Maruha Nichiro Foods Inc Hyaluronic acid production-promoting substance
JP2015097507A (en) * 2013-11-19 2015-05-28 国立大学法人九州大学 Mitochondria activator

Similar Documents

Publication Publication Date Title
US6855727B2 (en) Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
RU2402921C2 (en) Salts, addition compounds and complex compounds of guanidine-acetic acid
EP3320895B1 (en) Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine
US20090104278A1 (en) Food composition for recovery from fatigue
WO2004000297A1 (en) Nutritional or pharmaceutical compositions for increasing the creatine response of organisms
JP2022064912A (en) Method and composition for increasing muscle protein synthesis and/or functional strength in mammals as well as method of producing composition
CA2576516C (en) Food additive
EP3115047B1 (en) Debility preventative
JP2002065212A (en) Food composition for strengthening muscle, and muscle- strengthening agent
JP2002338473A (en) Anti-fatigue composition
JPH05213747A (en) Improvement in organic compound
US20040043442A1 (en) Use of betaine in functional products having blood pressure lowering effects
JPWO2003006037A1 (en) Therapeutic agent
CA2667667C (en) Solid or aqueous alkaline preparation comprising a creatine component, process for the production thereof and the use thereof
JP4873778B2 (en) Anti-fatigue
WO1998035664A1 (en) Athletic endurance increasing agent in food
JP2627660B2 (en) Methods for improving amino acid absorption in ruminants
JP4111428B2 (en) Osteoporosis preventive or therapeutic agent
JP4111429B2 (en) Osteoporosis preventive or therapeutic agent
JP7008452B2 (en) Highly absorbable oral tyrosine preparation
JPS63152963A (en) Nutrition supplementing food for building up stamina

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111129